Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 25 2023 - 8:00AM
Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”)
(Nasdaq: RANI), a clinical-stage biotherapeutics company focused on
the oral delivery of biologics and drugs, today announced the
company’s Chief Executive Officer, Talat Imran, will participate in
a fireside chat at the H.C. Wainwright BioConnect Investor
Conference on Tuesday, May 2, 2023 at 11:30 am E.T.
Interested parties can access the live webcast for this
conference from the Investor Relations section of the company's
website at www.ranitherapeutics.com. The webcast replay will be
available after the conclusion of the presentation.
Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company
focused on advancing technologies to enable the development of
orally administered biologics and drugs. Rani has developed the
RaniPill® capsule, which is a novel, proprietary and patented
platform technology, intended to replace subcutaneous injection or
intravenous infusion of biologics and drugs with oral dosing. Rani
has successfully conducted several preclinical and clinical studies
to evaluate safety, tolerability and bioavailability using
RaniPill® capsule technology. For more information,
visit ranitherapeutics.com.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
Rani Therapeutics (NASDAQ:RANI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rani Therapeutics (NASDAQ:RANI)
Historical Stock Chart
From Jul 2023 to Jul 2024